A routine injectable arthritis treatment for dogs and horses has been pulled nationwide after glass fibers turned up in retained samples.
Quick Take
- American Regent, Inc. Animal Health issued a nationwide recall of two lots of Adequan Canine and two lots of Adequan i.m.
- The company said the recall followed testing that found visible glass fiber material in internally retained samples.
- The recalled products were shipped to the consumer level, with distribution reaching veterinarians, wholesalers, and pharmacies.
- At the time of the recall, the company said it had not received reports of adverse events tied to the affected lots.
What the Recall Covered
The recall covered Adequan Canine Injection for dogs and Adequan i.m. Injection for horses. American Regent said it was removing lot 25011 and lot 3369 of the canine product, plus lot 24416 and lot 25265P of the equine product. The action applied nationwide and reached the consumer level, which means the company wanted the product out of clinics, pharmacies, and any other hands where it might still sit.
‘Glass Fibers’ Found Inside Dog and Horse Medications Prompt Urgent Nationwide Recall https://t.co/DwIWQV0OxB
— People Pets (@PEOPLEPets) August 7, 2026
The lot details matter because recalls can sound broad when they are not. This one was narrow in one sense and serious in another. The company did not pull every Adequan vial on the market. It pulled specific lots linked to a contamination concern, which is the standard move when a problem appears in a defined batch rather than across the whole product line.
Why the Company Acted
American Regent said the recall began after glass fibers were found during testing of internally retained samples. That is a key detail. It shows the trigger came from quality checks inside the manufacturing system, not from a public injury report first. The Food and Drug Administration said the product was recalled because of visible glass fiber material in the product.
The risk is not hard to understand. The Food and Drug Administration warned that an intramuscular injectable product containing particulate matter, such as glass fibers, may cause local irritation, swelling, inflammation, injection site pain, infection, or abscesses. That is why even a small foreign-material problem in an injectable drug gets treated as a safety issue, not a paperwork issue.
What Owners and Clinics Were Told to Do
The company told anyone with affected product not to use it and to stop distribution at once. Pet owners were told to contact their veterinarian if an animal had any problem that might be tied to the recalled medicine. Distributors, retailers, veterinary hospitals, and clinics were told to return remaining inventory or discard it. That kind of guidance is meant to cut off the chain quickly before more injections happen.
The recall notice also said no adverse events had been reported at the time of the announcement. That does not erase the contamination concern. It only means the company acted before the problem showed up in a wave of complaints or injuries. In product safety, that timing often matters more than a dramatic headline. A recall can be a warning shot, not a casualty report.
How This Fits the Bigger Picture
This case fits a familiar pattern in injectable drug quality problems. Foreign particles in a sterile or near-sterile product often trigger a precautionary recall before harm is documented. That approach can frustrate people who want a full root-cause answer right away, but it also reflects a simple rule: if the vial may contain a contaminant, the safest move is to pull it fast and sort out the details later.
What remains unanswered is the deeper manufacturing story. Public notices identified the affected lots and the contamination type, but they did not explain how the glass fibers got there. For dog owners, horse owners, and veterinarians, the immediate takeaway is more practical than dramatic: check lot numbers, stop using affected stock, and keep an eye on animals that may have already received one of the recalled injections.
Sources:
foxbusiness.com, people.com, usatoday.com
